 SAB Biotherapeutics Inc NASDAQ: SABS has reported positive Phase 2 safety and efficacy data demonstrating that SAB-185 met the criteria required to move to Phase 3 in the National Institutes of Health NIH COVID-19 ACTIV-2 Trial. SAB-185 is a fully human, specifically targeted, broadly neutralizing polyclonal antibody candidate for high-risk non-hospitalized patients with mild to moderate COVID-19. 